CPT code 88172 covers immediate cytologic evaluation of fine-needle aspiration specimens performed by a laboratory analyst to assess specimen adequacy at the time of aspiration. This point-of-care procedure helps determine whether sufficient diagnostic material was collected, which can reduce repeat procedures and expedite diagnosis for patients undergoing FNA for mass lesions or nodules. Nationally, rapid onsite evaluation is an important adjunct to cytopathology workflows and affects utilization patterns across outpatient and ambulatory procedure settings.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The overview addresses common payer coverage considerations and how this service is categorized across outpatient clinics, physician offices, and radiology procedure suites.

Readers will learn the clinical context for use of 88172, the typical sites of service, the role this immediate evaluation plays in specimen adequacy, and where to find additional billing and coding guidance. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes is noted where relevant. This summary is intended as a national reference for stakeholders seeking concise code-level context, payer scope, and service definition.